First-pass extracted concept

in vivo expression of therapeutic antibodies

Candidate: concept label1 source documents3 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Evidence Snippets

A promising alternative is to improve in vivo expression capabilities, which will reduce manufacturing burdens and improve safety and tolerability.

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 3 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1advantage statementsupports2025Source 1DOI PubMed

In situ expression may be especially beneficial for engineered antibody-like molecules by compensating for shorter half-lives and overcoming in vitro production and purification challenges.

Claim 2problem statementsupports2025Source 1DOI PubMed

Large-scale production and purification of complex antibody therapeutics remain costly and can restrict patient access.

Claim 3proposed solutionsupports2025Source 1DOI PubMed

Improving in vivo expression capabilities is presented as a promising alternative that could reduce manufacturing burdens and improve safety and tolerability for antibody therapeutics.